Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Figures corrected NBB
Corrected annual account filed for 2025.
Financials
Financial year 2025
CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE from Anderlecht, company number BE0403057962, closed financial year 2025 with a result of € -264,144 after tax. For that financial year CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE recorded revenue of € 580.7 million and equity of € 11.6 million. Compared with financial year 2024, the result moved from € 383,842 to € -264,144. The company made a loss. The company holds a healthy buffer. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 5, 2026.
€ 11.6 million
▼ 2% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -264,144
▼ still € 383,842 profit in 2024
Profit after tax over the fiscal year.
€ 2.4 million
▲ 22% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € 384,880.
People and assets in 2025
243.9
▲ 11.4 vs 2024
Average over the fiscal year, from the social balance sheet.
€ 13.5 million
▲ 8% vs 2024
€ 55,400 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 4.6 million
▼ 11% vs 2024
Of which on lease € 3.5 million.
Debts at end 2025
€ 58.2 million
▲ 10% vs 2024
€ 909,214 is repaid this year. At this pace the long-term loan is gone in ≈ 5 years.
€ 53 million
▲ 18% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 34 days on average.
€ 1.4 million
▲ 14% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | € 415,731,389 | € 460,373,997 | € 517,896,627 | € 580,721,056 | ▲ 12% |
| Profit after taxes | € 313,799 | € -77,193 | € 383,842 | € -264,144 | ▼ € 647,985 |
| Equity | € 11,575,194 | € 11,498,001 | € 11,881,843 | € 11,617,699 | ▼ 2% |
| Total debts | € 92,023,975 | € 99,514,735 | € 102,518,719 | € 116,074,205 | ▲ 13% |
| Cash | € 2,163,926 | € 1,494,916 | € 2,006,693 | € 2,439,399 | ▲ 22% |
| Land & buildings | € 3,889,007 | € 7,208,957 | € 7,704,586 | € 7,428,170 | ▼ 4% |
| Retained profit | € 342,376 | € 265,182 | € 649,024 | € 384,880 | ▼ 41% |
| Bank debt | € 47,267,672 | € 49,562,597 | € 52,838,097 | € 58,154,280 | ▲ 10% |
| Balance sheet total | € 104,641,166 | € 111,057,435 | € 114,460,900 | € 127,732,098 | ▲ 12% |
| Employees (FTE) | 224.1 | 228.7 | 232.5 | 243.9 | ▲ 11.4 |
By revenue, CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE ranks 2nd of 10 companies with main activity “Groothandel in farmaceutische producten” in Anderlecht that publish figures (fiscal year 2025).
Key figures of CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
Ask about CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE the way you would ask their accountant.
Answers from the filed annual accounts, the Belgian Official Gazette and the CBE register.
Connect ChatGPT or Claude for free- ChatGPT
- Claude
Free account, no payment card. Key figures unlimited, the annual accounts and deeds of 10 companies a month. Need more? Get in touch, we are looking for our first pilot users.
What happened to CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE?
What happened at CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- CHRISTOPHE LEFEVRE stepped down as director. NBB
- MARIELLE LAMBERT stepped down as director. NBB
- ARMAND PINTON stepped down as director. NBB
- PAUL RANSART stepped down as director. NBB
- SOBEDIP SA stepped down as director. NBB
- BERTRAND BUSSY stepped down as director. NBB
- Corrected annual accounts filed for financial year 2025. filed late Source: NBB ↗
- ANNE VALETTE stepped down as director. NBB
In short
From € 313,799 profit in 2022 to € 264,144 loss in 2025.
Paid € 428,611 in corporate taxes since 2022.
Best year ever: 2024, with € 383,842 profit.
Pays suppliers within 34 days on average.
Management
The shares are held by SOBEDIP SA (100%) and TIERS AUTRE (0%).
Directors
According to the 2025 annual accounts
PAUL RANSART
Director
since 2022 · until 2028
ANNE VALETTE
Director
since 2023 · until 2026
since 2022 · until 2028
CHRISTOPHE LEFEVRE
Director
since 2023 · until 2029
since 2023 · until 2029
ARMAND PINTON
Director
since 2023 · until 2029
since 2022 · until 2028
Shareholders
100%
TIERS AUTRE
0%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Humaniteitslaan 55
1070 Anderlecht
Rue Henri Lemaire(FB) 13 box A
7911 Frasnes-lez-Anvaing
Active since 8 August 1994
Middelweg 90
1130 Brussel
Active since 1 January 2000
Rue de Liège(CO) 31
6180 Courcelles
Active since 30 September 1994
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 2 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Similar companies in Anderlecht
Same main activity (Groothandel in farmaceutische producten), 14 active companies in Anderlecht, largest first.
€ 4.6 billion revenue · 2025
€ 448.8 million revenue · 2025
€ 131.2 million revenue · 2025
RECKITT BENCKISER (BELGIUM)SA/NV ou RECKITT BENCKISER HEALTHCARE (BELGIUM) NV/SA
€ 117.1 million revenue · 2023
€ 116.8 million revenue · 2025
€ 89.1 million revenue · 2025
Details
- Company number
- 0403.057.962
- VAT number
- BE 0403.057.962
- Registered office
- Humaniteitslaan 55, 1070 Anderlecht
- Names & denominations
- CENTRE EUROPEEN DE REPARTITION PHARMACEUTIQUE · CERP
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 1 January 1968
- Peppol
- Active · Active since 1 Jan 2001
- Activities · NACE
Groothandel in farmaceutische producten
Groothandel in farmaceutische en medische artikelen